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There was a reduction in the risk of a PONV event in the
post phase (OR  0.67, 95% CI 0.67 to 0.97, p  0.04).
The risk of PONV was significantly reduced with the ad-
ministration of prophylactic medications (OR  0.46,
95% CI 0.46 to 0.67). There was a reduction in the mean
number of PONV episodes in the post phase (1.81
events) versus the pre phase (1.47 events, p  0.02). A re-
duction in mean PONV management costs was observed
in the post phase ($8.31, SD 8.50) as compared to the
pre-phase ($10.23, SD 8.25, p  0.02). For mean pro-
phylactic costs, these were significantly higher in the
post-implementation phase when compared to the pre-
implementation phase ($1.64, SD 3.36 vs. $0.91, SD
2.43, p  0.013). Univariate sensitivity analyses revealed
that the economic results were sensitive to several param-
eters. CONCLUSION: The implementation of pre-printed
order forms for PONV prophylaxis and treatment appears
to be an effective and economically attractive strategy.
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OBJECTIVES: Whilst differences between Caucasian,
African and Asian menopausal women have been well
documented, the aim of this study is to explore the rela-
tionship between menopause, HRT use and aspects of
quality of life (QoL) across five European countries.
METHODS: A large-scale observational study of
women’s health in France, Germany, Italy, Poland, UK
was conducted with 7806 women, aged 45–65, and con-
sulting gynecologists or primary care physicians (n 
530). QoL was assessed with the Women’s Health Ques-
tionnaire (vasomotor, depressed mood and sexual behav-
ior scales). RESULTS: Mean age (range 52.5 to 54.7) and
time since menopause were similar across all countries.
Findings suggested differential use of HRT across Europe
(current or lapsed): high in Germany (68%), low in
France (50%) and Italy (49%) (chi-square  139, P 
0.001). We compared aspects of QoL between users and
non-users (stratified by time since menopause). Within 5
years of menopause HRT users experienced: significantly
fewer vasomotor symptoms than non-HRT users across
all countries (z  15,9 p  0.001); significantly less de-
pression (z  10.5, P  0.001) across all countries ex-
cept the UK, and significantly better sexual functioning in
Italy and Germany (z  7.6, p  0.001). For women
experiencing menopause over 5 years ago, HRT users
had better scores in sexual (z  12.2, P  0.001) and
mood (z  3.0, P  0.002) domains than non-users in
all countries, but no differences were observed for vaso-
motor symptoms. CONCLUSIONS: Within 5 years of
menopause, HRT improves those aspects of menopausal
symptoms which are most important to women at that
time in their lives (vasomotor symptoms, mood) irrespec-
tive of country. After 5 years, across countries, the im-
pact of vasomotor symptoms on women naturally de-
creases and thus HRT users no longer experience a
benefit over non-users. However, the benefits of HRT on
sexual functioning and mood continue. These findings
suggest that pooling European WHQ data may be appro-
priate.
NO SPECIFIC OR MULTIPLE
DISEASES-HEALTH POLICY
PHP1
THE ECONOMICS OF PARALLEL TRADE IN 
PHARMACEUTICALS: EXPERIENCES
FROM SWEDEN
Persson UB, Anell A
IHE, The Swedish Institute for Health Economics, Lund, 
Sweden
OBJECTIVES: To analyse the impact of parallel trade of
pharmaceuticals on welfare and innovation in the long
run and to estimate the impact of costs for pharmaceuti-
cals in some therapeutic areas in the short run. METH-
ODS: Identify arguments for and against parallel trade by
use of literature review and by interviewing agens in-
volved in parallel trade of pharmaceuticals. Official data
of prices and sales of pharmaceuticals are used to esti-
mate the impact of parallel trade on the drug bill. RE-
SULTS: In Europe the principle of free trade and the
harmonization of registration requirements for pharma-
ceuticals tend to force price convergence across markets,
i.e. a uniform ‘Euro price’. Parallel trade have reduced
annual costs for pharmaceuticals for treating ulcer re-
lated diseases by about 19 percent and for the treatment
of inhaled steroids of about 8 percent in Sweden. These
cost savings are compared with the excess costs for the
distribution and storage of parallel-imported products.
Comparison shows net cost savings for the ulcer related
diseases and inhaled steroids in the short run. CONCLU-
SIONS: There is a conflict between the principle of free
trade and the principle of intellectual property rights
(e.g., patent, brand-names, etc.). The purpose of intellec-
tual property rights is to provide economic incentives for
the innovative industry to develop new medicines. New
medicines are products with relatively high R&D costs,
difficult to finance without patent protection and price
discrimination.
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